{"protocolSection": {"identificationModule": {"nctId": "NCT00587288", "orgStudyIdInfo": {"id": "Res-5-0010"}, "organization": {"fullName": "Teva Branded Pharmaceutical Products R&D, Inc.", "class": "INDUSTRY"}, "briefTitle": "Efficacy and Safety Study of Reslizumab to Treat Poorly Controlled Asthma", "officialTitle": "An Efficacy and Safety Study of Reslizumab in the Treatment of Poorly Controlled Asthma in Subjects With Eosinophilic Airway Inflammation"}, "statusModule": {"statusVerifiedDate": "2016-07", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2008-04"}, "primaryCompletionDateStruct": {"date": "2010-03", "type": "ACTUAL"}, "completionDateStruct": {"date": "2010-03", "type": "ACTUAL"}, "studyFirstSubmitDate": "2008-01-04", "studyFirstSubmitQcDate": "2008-01-04", "studyFirstPostDateStruct": {"date": "2008-01-07", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2016-03-23", "resultsFirstSubmitQcDate": "2016-03-23", "resultsFirstPostDateStruct": {"date": "2016-04-26", "type": "ESTIMATED"}, "dispFirstSubmitDate": "2013-08-16", "dispFirstSubmitQcDate": "2013-08-16", "dispFirstPostDateStruct": {"date": "2013-08-26", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2016-07-18", "lastUpdatePostDateStruct": {"date": "2016-08-17", "type": "ESTIMATED"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Ception Therapeutics", "class": "INDUSTRY"}, "collaborators": [{"name": "Cephalon", "class": "INDUSTRY"}]}, "oversightModule": {"oversightHasDmc": true}, "descriptionModule": {"briefSummary": "The purpose of this study is to determine the effectiveness and safety of reslizumab in the treatment of subjects with poorly controlled asthma.", "detailedDescription": "Objectives:\n\nPrimary: To demonstrate the ability of reslizumab to improve asthma control in subjects with active asthma and eosinophilic airway inflammation.\n\nSecondary:\n\n* To study the ability of reslizumab to reduce induced sputum eosinophil (EOS) counts in subjects with asthma.\n* To study the ability of reslizumab to reduce the number of eosinophilic clinical asthma exacerbations (CAE) in subjects with asthma. A CAE is defined as a \u2265 20% decrease in forced expiratory volume in 1 second (FEV1; absolute value) from the baseline value or a requirement for emergency treatment of asthma, hospital admission for asthma or treatment with three or more days of oral corticosteroids (OCS) for asthma worsening.\n* To assess the safety and tolerability of reslizumab in subjects with asthma."}, "conditionsModule": {"conditions": ["Asthma"], "keywords": ["Cinquil\u2122", "Reslizumab"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE2"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "QUADRUPLE", "whoMasked": ["PARTICIPANT", "CARE_PROVIDER", "INVESTIGATOR", "OUTCOMES_ASSESSOR"]}}, "enrollmentInfo": {"count": 106, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Reslizumab 3 mg/kg", "type": "EXPERIMENTAL", "description": "Reslizumab 3 mg/kg intravenous (IV) on Day 0 of each 28-day (+/- 7 days) cycle, for 4 cycles", "interventionNames": ["Biological: Reslizumab"]}, {"label": "Placebo", "type": "PLACEBO_COMPARATOR", "description": "Saline placebo IV on Day 0 of each 28-day (+/- 7 days) cycle, for 4 cycles", "interventionNames": ["Other: Saline"]}], "interventions": [{"type": "BIOLOGICAL", "name": "Reslizumab", "armGroupLabels": ["Reslizumab 3 mg/kg"], "otherNames": ["Cinquil\u2122", "CEP-38072", "CTx55700"]}, {"type": "OTHER", "name": "Saline", "armGroupLabels": ["Placebo"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Mean Change From Baseline to End of Therapy in Asthma Control Questionnaire (ACQ) Score", "description": "The ACQ is a 7 question instrument. Each question has 7 possible answers of 0, 1, 2, 3, 4, 5, and 6. Each increasing value is an indication of poorer asthma control. At protocol specified visits, the participant answered questions 1 to 6, circling the response that best described how that participant was during the past week, on the basis of a daily diary for the week before the visit. At the actual visit, study center personnel reviewed the questions and responses with the participant and determined the response and score for question 7. The overall ACQ score was presented as the mean of these 7 individual scores and was a number between 0 and 6, but not necessarily an integer.", "timeFrame": "Baseline through End of Therapy (up to 15 weeks)"}], "secondaryOutcomes": [{"measure": "Percentage of ACQ Responders at End of Therapy", "description": "Responders were defined as participants achieving at least a 0.5 reduction from baseline to End of Therapy in ACQ score. The ACQ is a 7 question instrument. Each question has 7 possible answers of 0, 1, 2, 3, 4, 5, and 6. Each increasing value is an indication of poorer asthma control. At protocol specified visits, the participant answered questions 1 to 6, circling the response that best described how that participant was during the past week, on the basis of a daily diary for the week before the visit. At the actual visit, study center personnel reviewed the questions and responses with the participant and determined the response and score for question 7. The overall ACQ score was presented as the mean of these 7 individual scores and was a number between 0 and 6, but not necessarily an integer.", "timeFrame": "Baseline, End of Therapy (up to 15 weeks)"}, {"measure": "Change From Baseline to End of Therapy in Forced Expiratory Volume in the First Second (FEV1)", "description": "The change in FEV1 from baseline to End of Therapy was determined. FEV1 was measured during pulmonary function tests using standard spirometry measurements.", "timeFrame": "Baseline, End of Therapy (up to 15 weeks)"}, {"measure": "Change From Baseline to End of Therapy in Percent Predicted FEV1", "description": "The change in percent predicted FEV1 from baseline to End of Therapy was calculated from the FEV1 measured during pulmonary function tests using standard spirometry measurements. Each participant's percent predicted FEV1 was calculated by adjusting the FEV1 for age, sex, height and race. The percent predicted FEV1 was then calculated by comparing the predicted FEV1 to the observed FEV1 using the Crapo formula (Crapo et al 1981a, Crapo and Morris 1981b, Crapo et al 1982).", "timeFrame": "Baseline, End of Therapy (up to 15 weeks)"}, {"measure": "Mean Change From Baseline to End of Therapy in Induced Sputum Eosinophil Levels", "timeFrame": "End of Screening or Baseline, End of Therapy (up to 15 weeks)"}, {"measure": "Percentage of Participants With Clinical Asthma Exacerbations (CAEs)", "description": "A CAE was defined as a 20% or more decrease in forced expiratory volume in 1 second (FEV1, absolute value) from the baseline value, a requirement for emergency treatment of asthma, hospital admission for asthma, or treatment with 3 or more days of oral corticosteroids for asthma worsening.", "timeFrame": "up to 15 weeks"}, {"measure": "Number of Participants With Treatment-emergent Adverse Events (AEs), Serious AEs, and AEs Leading to Study Discontinuation", "description": "Participants may have been included in more than 1 category. AEs summarized were those that began or worsened after dispensation of the study drug and before 30 days after the last dose of study drug. If the severity of an AE was missing, the AE was reported as \"severe.\" If drug relationship of an AE was missing, the AE was reported as \"probably related.\" WFT=withdrawn from treatment.", "timeFrame": "From start of study drug through 15 weeks + 30 days"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* written informed consent\n* male or female subjects aged \u2265 18 to 75 years at time of screening\n* female if she is of non-childbearing potential, or of childbearing potential and willing to use specific barrier methods specified in protocol\n* confirmation of asthma\n* symptoms consistent with a diagnosis of asthma that is poorly controlled with an inhaled corticosteroid as determined by an Asthma Control Questionnaire (ACQ) score \u2265 1.5\n* requirement for treatment with high dose daily fluticasone and at least one other agent for the treatment of asthma not specifically excluded in the protocol\n* requirement for \\>/= 3% eosinophils in induced sputum at Screening\n\nExclusion Criteria:\n\n* a clinically important event that would interfere with study schedule or procedure or compromise subject safety\n* a diagnosis of hypereosinophilic syndrome\n* an underlying lung disorder\n* a current smoker\n* use of systemic immunosuppressive agents within 6 months of study\n* current use of systemic corticosteroids\n* received attenuated live attenuated vaccines within three months prior to study entry\n* expected to be poorly compliant with study drug, procedures, visits\n* aggravating factors that are inadequately controlled\n* participation in any investigational drug or device study within 30 days prior to study entry\n* participation in biologics study within 3 months prior to study entry\n* receipt of anti-human interleukin-5 (hIL-5) antibody within 6 months of study entry\n* female subjects who are pregnant or nursing\n* concurrent infection or disease that may preclude assessment of eosinophilic esophagitis\n* concurrent immunodeficiency (human immunodeficiency \\[HIV\\], or acquired immunodeficiency syndrome \\[AIDS\\] or congenital immunodeficiency).\n* current suspected drug and/or alcohol abuse", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "maximumAge": "75 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Sponsor's Medical Expert, MD", "affiliation": "Cephalon (Ception)", "role": "STUDY_DIRECTOR"}], "locations": [{"facility": "Children'S Hospital of Orange County-Pediatric Subspecialty Faculty", "city": "Orange", "state": "California", "zip": "92868", "country": "United States", "geoPoint": {"lat": 33.78779, "lon": -117.85311}}, {"facility": "Allergy & Clinical Research Center", "city": "Centennial", "state": "Colorado", "zip": "80112", "country": "United States", "geoPoint": {"lat": 39.57916, "lon": -104.87692}}, {"facility": "Asthma & Allergy Associates, P.C.", "city": "Colorado Springs", "state": "Colorado", "zip": "80907", "country": "United States", "geoPoint": {"lat": 38.83388, "lon": -104.82136}}, {"facility": "National Jewish Medical & Research Center", "city": "Denver", "state": "Colorado", "zip": "80206", "country": "United States", "geoPoint": {"lat": 39.73915, "lon": -104.9847}}, {"facility": "Sneeze, Wheeze & Itch Associates, LLC", "city": "Normal", "state": "Illinois", "zip": "61761", "country": "United States", "geoPoint": {"lat": 40.5142, "lon": -88.99063}}, {"facility": "Pulmonary Disease & Critical Care Associates, P.A.", "city": "Columbia", "state": "Maryland", "zip": "21044", "country": "United States", "geoPoint": {"lat": 39.24038, "lon": -76.83942}}, {"facility": "Brigham and Women's Hospital", "city": "Boston", "state": "Massachusetts", "zip": "02115", "country": "United States", "geoPoint": {"lat": 42.35843, "lon": -71.05977}}, {"facility": "Clinical Research Institute", "city": "Minneapolis", "state": "Minnesota", "zip": "55402", "country": "United States", "geoPoint": {"lat": 44.97997, "lon": -93.26384}}, {"facility": "Washington University of School of Medicine", "city": "St. Louis", "state": "Missouri", "zip": "63110", "country": "United States", "geoPoint": {"lat": 38.62727, "lon": -90.19789}}, {"facility": "The Asthma & Allergy Center", "city": "Papillion", "state": "Nebraska", "zip": "68046", "country": "United States", "geoPoint": {"lat": 41.15444, "lon": -96.04224}}, {"facility": "Health Sciences Research at Asthma & Allergy", "city": "Cortland", "state": "New York", "zip": "13045", "country": "United States", "geoPoint": {"lat": 42.60118, "lon": -76.18048}}, {"facility": "Wake Forest Univeristy Health Services", "city": "Winston-Salem", "state": "North Carolina", "zip": "27157", "country": "United States", "geoPoint": {"lat": 36.09986, "lon": -80.24422}}, {"facility": "David Bernstein", "city": "Cincinnati", "state": "Ohio", "zip": "45229", "country": "United States", "geoPoint": {"lat": 39.12713, "lon": -84.51435}}, {"facility": "Toledo Center for Clinical Research", "city": "Sylvania", "state": "Ohio", "zip": "43560", "country": "United States", "geoPoint": {"lat": 41.71894, "lon": -83.71299}}, {"facility": "Allergy, Asthma and Clinical Research Center", "city": "Oklahoma City", "state": "Oklahoma", "zip": "73120", "country": "United States", "geoPoint": {"lat": 35.46756, "lon": -97.51643}}, {"facility": "Clinical Research Institute of Southern Oregon", "city": "Medford", "state": "Oregon", "zip": "97504", "country": "United States", "geoPoint": {"lat": 42.32652, "lon": -122.87559}}, {"facility": "Allergy and Asthma Specialists", "city": "Blue Bell", "state": "Pennsylvania", "zip": "19422", "country": "United States", "geoPoint": {"lat": 40.15233, "lon": -75.26629}}, {"facility": "University of Pittsburgh", "city": "Pittsburgh", "state": "Pennsylvania", "zip": "15213", "country": "United States", "geoPoint": {"lat": 40.44062, "lon": -79.99589}}, {"facility": "Vanderbilt Asthma Sinus Allergy Program & Research Centers", "city": "Nashville", "state": "Tennessee", "zip": "37203", "country": "United States", "geoPoint": {"lat": 36.16589, "lon": -86.78444}}, {"facility": "Virginia Adult & Pediatric Allergy and Asthma", "city": "Richmond", "state": "Virginia", "zip": "23229", "country": "United States", "geoPoint": {"lat": 37.55376, "lon": -77.46026}}, {"facility": "Virginia Commonwealth University", "city": "Richmond", "state": "Virginia", "zip": "23298", "country": "United States", "geoPoint": {"lat": 37.55376, "lon": -77.46026}}, {"facility": "Asthma, Inc", "city": "Seatle", "state": "Washington", "zip": "98105", "country": "United States", "geoPoint": {"lat": 47.60621, "lon": -122.33207}}, {"facility": "Allergy, Asthma and Sinus Center", "city": "Greenfield", "state": "Wisconsin", "zip": "53228", "country": "United States", "geoPoint": {"lat": 42.9614, "lon": -88.01259}}, {"facility": "University of Wisconsin-Madison, Allergy/Asthma Clinical Research Unit", "city": "Madison", "state": "Wisconsin", "zip": "53972", "country": "United States", "geoPoint": {"lat": 43.07305, "lon": -89.40123}}, {"facility": "Heritage Medical Research Clinic, University of Calgary", "city": "Calgary", "state": "Alberta", "zip": "T2N4N1", "country": "Canada", "geoPoint": {"lat": 51.05011, "lon": -114.08529}}, {"facility": "St. Joseph's Healthcare", "city": "Hamilton", "state": "Ontario", "zip": "L8N 4A6", "country": "Canada", "geoPoint": {"lat": 43.25011, "lon": -79.84963}}, {"facility": "Queen's University, Richardson's House", "city": "Kingston", "state": "Ontario", "zip": "K7L 2V6", "country": "Canada", "geoPoint": {"lat": 44.22976, "lon": -76.48101}}, {"facility": "The Ottawa Hospital", "city": "Ottawa", "state": "Ontario", "zip": "K1H 8L6", "country": "Canada", "geoPoint": {"lat": 45.41117, "lon": -75.69812}}, {"facility": "Hopital du Sacre-Couer de Montreal", "city": "Montreal", "state": "Quebec", "zip": "H4J1C5", "country": "Canada", "geoPoint": {"lat": 45.50884, "lon": -73.58781}}, {"facility": "Hopital Laval", "city": "Quebec", "zip": "G1V4G5", "country": "Canada", "geoPoint": {"lat": 46.81228, "lon": -71.21454}}]}, "referencesModule": {"references": [{"pmid": "21852542", "type": "BACKGROUND", "citation": "Castro M, Mathur S, Hargreave F, Boulet LP, Xie F, Young J, Wilkins HJ, Henkel T, Nair P; Res-5-0010 Study Group. Reslizumab for poorly controlled, eosinophilic asthma: a randomized, placebo-controlled study. Am J Respir Crit Care Med. 2011 Nov 15;184(10):1125-32. doi: 10.1164/rccm.201103-0396OC. Epub 2011 Aug 18."}]}}, "resultsSection": {"participantFlowModule": {"groups": [{"id": "FG000", "title": "Reslizumab 3 mg/kg", "description": "reslizumab 3 mg/kg intravenous (IV) on Day 0 of each 28-day (+/- 7 days) cycle, for 4 cycles"}, {"id": "FG001", "title": "Placebo", "description": "saline placebo IV on Day 0 of each 28-day (+/- 7 days) cycle, for 4 cycles"}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "53"}, {"groupId": "FG001", "numSubjects": "53"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "50"}, {"groupId": "FG001", "numSubjects": "44"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "3"}, {"groupId": "FG001", "numSubjects": "9"}]}], "dropWithdraws": [{"type": "Adverse Event", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "1"}]}, {"type": "Lack of Efficacy", "reasons": [{"groupId": "FG000", "numSubjects": "2"}, {"groupId": "FG001", "numSubjects": "8"}]}, {"type": "Protocol Violation", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "0"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "Reslizumab 3 mg/kg", "description": "reslizumab 3 mg/kg IV on Day 0 of each 28-day (+/- 7 days) cycle, for 4 cycles"}, {"id": "BG001", "title": "Placebo", "description": "saline placebo IV on Day 0 of each 28-day (+/- 7 days) cycle, for 4 cycles"}, {"id": "BG002", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "53"}, {"groupId": "BG001", "value": "53"}, {"groupId": "BG002", "value": "106"}]}], "measures": [{"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "44.9", "spread": "13.94"}, {"groupId": "BG001", "value": "45.8", "spread": "11.74"}, {"groupId": "BG002", "value": "45.4", "spread": "12.83"}]}]}]}, {"title": "Age, Customized", "paramType": "NUMBER", "unitOfMeasure": "participants", "classes": [{"title": "18 to < 45 years", "categories": [{"measurements": [{"groupId": "BG000", "value": "28"}, {"groupId": "BG001", "value": "20"}, {"groupId": "BG002", "value": "48"}]}]}, {"title": "45 to < 65 years", "categories": [{"measurements": [{"groupId": "BG000", "value": "19"}, {"groupId": "BG001", "value": "32"}, {"groupId": "BG002", "value": "51"}]}]}, {"title": ">/= 65 years", "categories": [{"measurements": [{"groupId": "BG000", "value": "6"}, {"groupId": "BG001", "value": "1"}, {"groupId": "BG002", "value": "7"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "34"}, {"groupId": "BG001", "value": "29"}, {"groupId": "BG002", "value": "63"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "19"}, {"groupId": "BG001", "value": "24"}, {"groupId": "BG002", "value": "43"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Mean Change From Baseline to End of Therapy in Asthma Control Questionnaire (ACQ) Score", "description": "The ACQ is a 7 question instrument. Each question has 7 possible answers of 0, 1, 2, 3, 4, 5, and 6. Each increasing value is an indication of poorer asthma control. At protocol specified visits, the participant answered questions 1 to 6, circling the response that best described how that participant was during the past week, on the basis of a daily diary for the week before the visit. At the actual visit, study center personnel reviewed the questions and responses with the participant and determined the response and score for question 7. The overall ACQ score was presented as the mean of these 7 individual scores and was a number between 0 and 6, but not necessarily an integer.", "populationDescription": "Intent-to-treat (ITT) Analysis Set: all participants who received any amount of randomly assigned study drug.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "units on a scale", "timeFrame": "Baseline through End of Therapy (up to 15 weeks)", "groups": [{"id": "OG000", "title": "Reslizumab 3 mg/kg", "description": "reslizumab 3 mg/kg intravenous (IV) on Day 0 of each 28-day (+/- 7 days) cycle, for 4 cycles"}, {"id": "OG001", "title": "Placebo", "description": "saline placebo IV on Day 0 of each 28-day (+/- 7 days) cycle, for 4 cycles"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "53"}, {"groupId": "OG001", "value": "53"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.7", "spread": "1.02"}, {"groupId": "OG001", "value": "-0.3", "spread": "1.01"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.0541", "pValueComment": "The p-value for the treatment comparison is based on the ANCOVA with adjustment for stratification factor and for variable at baseline.", "statisticalMethod": "ANCOVA", "paramType": "Adjusted mean difference", "paramValue": "-0.38", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.76", "ciUpperLimit": "0.01", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.194"}]}, {"type": "SECONDARY", "title": "Percentage of ACQ Responders at End of Therapy", "description": "Responders were defined as participants achieving at least a 0.5 reduction from baseline to End of Therapy in ACQ score. The ACQ is a 7 question instrument. Each question has 7 possible answers of 0, 1, 2, 3, 4, 5, and 6. Each increasing value is an indication of poorer asthma control. At protocol specified visits, the participant answered questions 1 to 6, circling the response that best described how that participant was during the past week, on the basis of a daily diary for the week before the visit. At the actual visit, study center personnel reviewed the questions and responses with the participant and determined the response and score for question 7. The overall ACQ score was presented as the mean of these 7 individual scores and was a number between 0 and 6, but not necessarily an integer.", "populationDescription": "ITT Analysis Set: all participants who received any amount of randomly assigned study drug.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "percentage of participants", "timeFrame": "Baseline, End of Therapy (up to 15 weeks)", "groups": [{"id": "OG000", "title": "Reslizumab 3 mg/kg", "description": "reslizumab 3 mg/kg intravenous (IV) on Day 0 of each 28-day (+/- 7 days) cycle, for 4 cycles"}, {"id": "OG001", "title": "Placebo", "description": "saline placebo IV on Day 0 of each 28-day (+/- 7 days) cycle, for 4 cycles"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "53"}, {"groupId": "OG001", "value": "53"}]}], "classes": [{"title": "Responder = yes", "categories": [{"measurements": [{"groupId": "OG000", "value": "55"}, {"groupId": "OG001", "value": "36"}]}]}, {"title": "Responder = no", "categories": [{"measurements": [{"groupId": "OG000", "value": "45"}, {"groupId": "OG001", "value": "64"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.0848", "pValueComment": "The p-value for the treatment comparison was based on logistic regression with adjustment for stratification factor.", "statisticalMethod": "Regression, Logistic", "paramType": "Odds Ratio (OR)", "paramValue": "2.01", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.91", "ciUpperLimit": "4.46"}]}, {"type": "SECONDARY", "title": "Change From Baseline to End of Therapy in Forced Expiratory Volume in the First Second (FEV1)", "description": "The change in FEV1 from baseline to End of Therapy was determined. FEV1 was measured during pulmonary function tests using standard spirometry measurements.", "populationDescription": "ITT Analysis Set: all participants who received any amount of randomly assigned study drug with an assessment at Baseline and End of Therapy.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "L", "timeFrame": "Baseline, End of Therapy (up to 15 weeks)", "groups": [{"id": "OG000", "title": "Reslizumab 3 mg/kg", "description": "reslizumab 3 mg/kg intravenous (IV) on Day 0 of each 28-day (+/- 7 days) cycle, for 4 cycles"}, {"id": "OG001", "title": "Placebo", "description": "saline placebo IV on Day 0 of each 28-day (+/- 7 days) cycle, for 4 cycles"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "52"}, {"groupId": "OG001", "value": "52"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.18", "spread": "0.372"}, {"groupId": "OG001", "value": "-0.08", "spread": "0.413"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.0023", "pValueComment": "The p-value for the treatment comparison was based on the ANCOVA with adjustment for stratification factor and for variable at baseline.", "statisticalMethod": "ANCOVA", "paramType": "Adjusted mean difference", "paramValue": "0.240", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.088", "ciUpperLimit": "0.392", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.077"}]}, {"type": "SECONDARY", "title": "Change From Baseline to End of Therapy in Percent Predicted FEV1", "description": "The change in percent predicted FEV1 from baseline to End of Therapy was calculated from the FEV1 measured during pulmonary function tests using standard spirometry measurements. Each participant's percent predicted FEV1 was calculated by adjusting the FEV1 for age, sex, height and race. The percent predicted FEV1 was then calculated by comparing the predicted FEV1 to the observed FEV1 using the Crapo formula (Crapo et al 1981a, Crapo and Morris 1981b, Crapo et al 1982).", "populationDescription": "ITT Analysis Set: all participants who received any amount of randomly assigned study drug with an assessment at Baseline and End of Therapy.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "percent predicted FEV1", "timeFrame": "Baseline, End of Therapy (up to 15 weeks)", "groups": [{"id": "OG000", "title": "Reslizumab 3 mg/kg", "description": "reslizumab 3 mg/kg intravenous (IV) on Day 0 of each 28-day (+/- 7 days) cycle, for 4 cycles"}, {"id": "OG001", "title": "Placebo", "description": "saline placebo IV on Day 0 of each 28-day (+/- 7 days) cycle, for 4 cycles"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "52"}, {"groupId": "OG001", "value": "52"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "6.2", "spread": "11.76"}, {"groupId": "OG001", "value": "-2.4", "spread": "12.93"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.0010", "pValueComment": "The p-value for the treatment comparison was based on the ANCOVA with adjustment for stratification factor and for variable at baseline.", "statisticalMethod": "ANCOVA", "paramType": "Adjusted mean difference", "paramValue": "7.98", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "3.30", "ciUpperLimit": "12.65", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "2.36"}]}, {"type": "SECONDARY", "title": "Mean Change From Baseline to End of Therapy in Induced Sputum Eosinophil Levels", "populationDescription": "ITT Analysis Set: all participants who received any amount of randomly assigned study drug with an assessment at Baseline and End of Therapy.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "percent change in eosinophil levels", "timeFrame": "End of Screening or Baseline, End of Therapy (up to 15 weeks)", "groups": [{"id": "OG000", "title": "Reslizumab 3 mg/kg", "description": "reslizumab 3 mg/kg intravenous (IV) on Day 0 of each 28-day (+/- 7 days) cycle, for 4 cycles"}, {"id": "OG001", "title": "Placebo", "description": "saline placebo IV on Day 0 of each 28-day (+/- 7 days) cycle, for 4 cycles"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "38"}, {"groupId": "OG001", "value": "36"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-82.0", "spread": "66.88"}, {"groupId": "OG001", "value": "45.9", "spread": "265.79"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.0068", "pValueComment": "The p-value for the treatment comparison was based on the ANCOVA with adjustment for stratification factor and for variable at baseline. The difference between reslizumab 3.0 mg/kg and placebo groups was from comparison of the least square means.", "statisticalMethod": "ANCOVA", "paramType": "Adjusted mean difference", "paramValue": "-125.29", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-214.81", "ciUpperLimit": "-35.77", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "44.885"}]}, {"type": "SECONDARY", "title": "Percentage of Participants With Clinical Asthma Exacerbations (CAEs)", "description": "A CAE was defined as a 20% or more decrease in forced expiratory volume in 1 second (FEV1, absolute value) from the baseline value, a requirement for emergency treatment of asthma, hospital admission for asthma, or treatment with 3 or more days of oral corticosteroids for asthma worsening.", "populationDescription": "ITT Analysis Set: all participants who received any amount of randomly assigned study drug.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "percentage of participants", "timeFrame": "up to 15 weeks", "groups": [{"id": "OG000", "title": "Reslizumab 3 mg/kg", "description": "reslizumab 3 mg/kg intravenous (IV) on Day 0 of each 28-day (+/- 7 days) cycle, for 4 cycles"}, {"id": "OG001", "title": "Placebo", "description": "saline placebo IV on Day 0 of each 28-day (+/- 7 days) cycle, for 4 cycles"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "53"}, {"groupId": "OG001", "value": "53"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "8"}, {"groupId": "OG001", "value": "19"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.0833", "pValueComment": "The p-value for the treatment comparison was based on logistic regression with adjustment for stratification factor.", "statisticalMethod": "Regression, Logistic", "paramType": "Odds Ratio (OR)", "paramValue": "0.33", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.10", "ciUpperLimit": "1.15"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Kaplan-Meier estimate of time to first CAE. (First quartile, median and third quartile \"survival\" times with 95% confidence intervals (ie, time to first CAE) could not be estimated since the proportion of patients experiencing CAE was too low. Therefore, the only number presented in regard to the Kaplan-Meier analysis is the p-value of the log-rank test, below. )", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.0809", "statisticalMethod": "Log Rank", "statisticalComment": "The p value for the treatment comparison was based on log rank test adjusting for stratification factor (ie, ACQ score \u22642 and \\>2)."}]}, {"type": "SECONDARY", "title": "Number of Participants With Treatment-emergent Adverse Events (AEs), Serious AEs, and AEs Leading to Study Discontinuation", "description": "Participants may have been included in more than 1 category. AEs summarized were those that began or worsened after dispensation of the study drug and before 30 days after the last dose of study drug. If the severity of an AE was missing, the AE was reported as \"severe.\" If drug relationship of an AE was missing, the AE was reported as \"probably related.\" WFT=withdrawn from treatment.", "populationDescription": "ITT Analysis Set: all participants who received any amount of randomly assigned study drug with an assessment at Baseline and End of Therapy.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "participants", "timeFrame": "From start of study drug through 15 weeks + 30 days", "groups": [{"id": "OG000", "title": "Reslizumab 3 mg/kg", "description": "Reslizumab 3 mg/kg intravenous (IV) on Day 0 of each 28-day (+/- 7 days) cycle, for 4 cycles"}, {"id": "OG001", "title": "Placebo", "description": "Saline placebo IV on Day 0 of each 28-day (+/- 7 days) cycle, for 4 cycles"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "53"}, {"groupId": "OG001", "value": "53"}]}], "classes": [{"title": "Any AE", "categories": [{"measurements": [{"groupId": "OG000", "value": "38"}, {"groupId": "OG001", "value": "42"}]}]}, {"title": "Severe or life-threatening AE", "categories": [{"measurements": [{"groupId": "OG000", "value": "3"}, {"groupId": "OG001", "value": "1"}]}]}, {"title": "Treatment-related AE", "categories": [{"measurements": [{"groupId": "OG000", "value": "12"}, {"groupId": "OG001", "value": "8"}]}]}, {"title": "Deaths", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "Serious AEs other than death", "categories": [{"measurements": [{"groupId": "OG000", "value": "2"}, {"groupId": "OG001", "value": "1"}]}]}, {"title": "Treatment-related serious AEs", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "WFT or study due to AEs", "categories": [{"measurements": [{"groupId": "OG000", "value": "1"}, {"groupId": "OG001", "value": "1"}]}]}, {"title": "WFT or study due to treatment-related AEs", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "1"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "5", "timeFrame": "From start of study drug through 15 weeks + 30 days", "eventGroups": [{"id": "EG000", "title": "Reslizumab 3 mg/kg", "description": "reslizumab 3 mg/kg IV on Day 0 of each 28-day (+/- 7 days) cycle, for 4 cycles", "seriousNumAffected": 2, "seriousNumAtRisk": 53, "otherNumAffected": 17, "otherNumAtRisk": 53}, {"id": "EG001", "title": "Placebo", "description": "saline placebo IV on Day 0 of each 28-day (+/- 7 days) cycle, for 4 cycles", "seriousNumAffected": 1, "seriousNumAtRisk": 53, "otherNumAffected": 17, "otherNumAtRisk": 53}], "seriousEvents": [{"term": "PNEUMONIA", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 10.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 53}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 53}]}, {"term": "ASTHMA", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 10.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 53}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 53}]}, {"term": "HYPERTENSION", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA 10.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 53}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 53}]}], "otherEvents": [{"term": "FATIGUE", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 10.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 4, "numAffected": 4, "numAtRisk": 53}, {"groupId": "EG001", "numEvents": 2, "numAffected": 2, "numAtRisk": 53}]}, {"term": "BRONCHITIS", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 10.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 53}, {"groupId": "EG001", "numEvents": 3, "numAffected": 3, "numAtRisk": 53}]}, {"term": "NASOPHARYNGITIS", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 10.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 14, "numAffected": 11, "numAtRisk": 53}, {"groupId": "EG001", "numEvents": 6, "numAffected": 5, "numAtRisk": 53}]}, {"term": "UPPER RESPIRATORY TRACT INFECTION", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 10.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 3, "numAffected": 2, "numAtRisk": 53}, {"groupId": "EG001", "numEvents": 5, "numAffected": 5, "numAtRisk": 53}]}, {"term": "HEADACHE", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 10.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 3, "numAffected": 2, "numAtRisk": 53}, {"groupId": "EG001", "numEvents": 5, "numAffected": 5, "numAtRisk": 53}]}, {"term": "PHARYNGOLARYNGEAL PAIN", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 10.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 3, "numAffected": 3, "numAtRisk": 53}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 53}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictionType": "OTHER", "restrictiveAgreement": true, "otherDetails": "Sponsor has the right 60 days before submission for publication to review/provide comments. If the Sponsor's review shows that potentially patentable subject matter would be disclosed, publication or public disclosure shall be delayed for up to 90 additional days in order for the Sponsor, or Sponsor's designees, to file the necessary patent applications. In multicenter trials, each PI will postpone single center publications until after disclosure or publication of multicenter data."}, "pointOfContact": {"title": "Director, Clinical Research", "organization": "Teva Branded Pharmaceutical Products, R&D Inc.", "email": "ustevatrials@tevapharm.com", "phone": "215-591-3000"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24"}, "conditionBrowseModule": {"meshes": [{"id": "D000001249", "term": "Asthma"}], "ancestors": [{"id": "D000001982", "term": "Bronchial Diseases"}, {"id": "D000012140", "term": "Respiratory Tract Diseases"}, {"id": "D000008173", "term": "Lung Diseases, Obstructive"}, {"id": "D000008171", "term": "Lung Diseases"}, {"id": "D000012130", "term": "Respiratory Hypersensitivity"}, {"id": "D000006969", "term": "Hypersensitivity, Immediate"}, {"id": "D000006967", "term": "Hypersensitivity"}, {"id": "D000007154", "term": "Immune System Diseases"}], "browseLeaves": [{"id": "M4556", "name": "Asthma", "asFound": "Asthma", "relevance": "HIGH"}, {"id": "M10293", "name": "Inflammation", "relevance": "LOW"}, {"id": "M5258", "name": "Bronchial Diseases", "relevance": "LOW"}, {"id": "M14977", "name": "Respiratory Tract Diseases", "relevance": "LOW"}, {"id": "M11168", "name": "Lung Diseases", "relevance": "LOW"}, {"id": "M11170", "name": "Lung Diseases, Obstructive", "relevance": "LOW"}, {"id": "M10018", "name": "Hypersensitivity", "relevance": "LOW"}, {"id": "M14967", "name": "Respiratory Hypersensitivity", "relevance": "LOW"}, {"id": "M10020", "name": "Hypersensitivity, Immediate", "relevance": "LOW"}, {"id": "M10200", "name": "Immune System Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC08", "name": "Respiratory Tract (Lung and Bronchial) Diseases"}, {"abbrev": "BC20", "name": "Immune System Diseases"}, {"abbrev": "All", "name": "All Conditions"}, {"abbrev": "BC23", "name": "Symptoms and General Pathology"}]}, "interventionBrowseModule": {"meshes": [{"id": "C000515492", "term": "Reslizumab"}], "ancestors": [{"id": "D000018927", "term": "Anti-Asthmatic Agents"}, {"id": "D000019141", "term": "Respiratory System Agents"}], "browseLeaves": [{"id": "M287460", "name": "Reslizumab", "asFound": "Diaphragmatic breathing exercises", "relevance": "HIGH"}, {"id": "M20963", "name": "Anti-Asthmatic Agents", "relevance": "LOW"}, {"id": "M21137", "name": "Respiratory System Agents", "relevance": "LOW"}], "browseBranches": [{"abbrev": "Resp", "name": "Respiratory System Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}]}}, "hasResults": true}